NF-κB blockade by PS-1145, an IκB kinase (IKK) inhibitor, is effective at suppressing the growth of imatinib-resistant CML cell lines and bone marrow (BM) cells of imatinib-resistant CML-chronic phase (CML-CP) patient bone marrow (BM) cells in vitro32. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.